Psoriasis drug market expected to double to $6.8 Billion in 2019, driven by biologics penetration and Interleukin/TNF-alpha inhibitors

The continued uptake of marketed and emerging interleukin and TNF-alpha inhibitors, along with a twofold increase in the penetration of biologics in the moderate-to-severe population, will drive the psoriasis drug market to double from $3.4 billion in 2009 to $6.8 billion in 2019 in the USA, France, Germany, Italy, Spain, the UK and Japan, according to advisory firm Decision Resources.

DR's Pharmacor 2010 findings reveal that, while Amgen/GlaxoSmithKline/Pfizer/Takeda's Enbrel (etanercept) maintained its market dominance in 2009 - earning $1.3 billion in sales - it will face stiff competition from Abbott/Eisai's Humira (adalimumab) and the interleukin inhibitors. The uptake of interleukin inhibitors such as Centocor Ortho Biotech/Janssen-Cilag's Stelara (ustekinumab) and Abbott's briakinumab, combined with the entry of biosimilar formulations, will reduce Enbrel's market share from more than one third of sales in 2009 to less than one-quarter of sales in 2019.

Humira will overtake Enbrel next year